CIK 0001785530
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Werewolf Therapeutics, Inc.
Sign in to watch- Ticker
- HOWL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 823523180
- Phone
- +1 617-952-0555
- Business address
- 303 WYMAN STREET, SUITE 300, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-24 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −88,802 | $0.98 | $87K | 5,168,303 |
| 2025-11-24 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −88,802 | $0.98 | $87K | 5,168,303 |
| 2025-11-24 | EVNIN LUKE Director | Sale 10b5-1 | −56,992 | $0.98 | $56K | 3,314,848 |
| 2025-11-21 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −64,331 | $0.83 | $53K | 5,257,105 |
| 2025-11-21 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −64,331 | $0.83 | $53K | 5,257,105 |
| 2025-11-21 | EVNIN LUKE Director | Sale 10b5-1 | −41,287 | $0.83 | $34K | 3,371,840 |
| 2025-11-20 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −41,152 | $0.89 | $37K | 5,321,436 |
| 2025-11-20 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −41,152 | $0.89 | $37K | 5,321,436 |
| 2025-11-20 | EVNIN LUKE Director | Sale 10b5-1 | −26,411 | $0.89 | $24K | 3,413,127 |
| 2025-11-19 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −66,324 | $0.94 | $62K | 5,362,588 |
| 2025-11-19 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −66,324 | $0.94 | $62K | 5,362,588 |
| 2025-11-19 | EVNIN LUKE Director | Sale 10b5-1 | −42,566 | $0.94 | $40K | 3,439,538 |
| 2025-11-18 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −52,627 | $0.93 | $49K | 5,428,912 |
| 2025-11-18 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −52,627 | $0.93 | $49K | 5,428,912 |
| 2025-11-18 | EVNIN LUKE Director | Sale 10b5-1 | −33,776 | $0.93 | $31K | 3,482,104 |
| 2025-11-17 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −57,061 | $0.95 | $54K | 5,481,539 |
| 2025-11-17 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −57,061 | $0.95 | $54K | 5,481,539 |
| 2025-11-17 | EVNIN LUKE Director | Sale 10b5-1 | −36,621 | $0.95 | $35K | 3,515,880 |
| 2025-11-14 | MPM BioVentures 2014, L.P. 10% owner | Sale 10b5-1 | −61,640 | $0.93 | $57K | 5,538,600 |
| 2025-11-14 | GADICKE ANSBERT 10% owner | Sale 10b5-1 | −61,640 | $0.93 | $57K | 5,538,600 |
Page 6 of 17 · 335 trades